Table 1.
Characteristics of the included studies on MRSA prevalence
| Region/Study | Country | Study perioid | Setting | No. of BSI isolates | No. of GP bacteria (%) | No. of MRSA (%) | MRSA rates in S. aureus |
|---|---|---|---|---|---|---|---|
| Africa | |||||||
| El-Mahallawy et al. 2005 [43] | Egypt | 1999 | Children with ST or HM | 328 | 168 (51.2) | 18 (5.5) | 40.9% |
| Arega et al. 2018 [49] | Ethiopia | 2011–2012 | Adults with ST or HM | 82 | 43 (52.4) | 23 (28.0) | 74.2% |
| Obeng-Nkrumah et al. 2015 [41] | Ghana | 2010–2013 | Adults and children with ST or HM | 93 | 40 (43.0) | 0 (0.0) | NA |
| Mvalo et al. 2018 [38] | South Africa | 2012–2014 | Children with ST or HM | 173 | 85 (49.1) | 2 (1.2) | NA |
| Lubwama et al. 2019 [30] | Uganda | 2014 | Adults and children with ST or HM | 33 | 11 (33.3) | 1 (3.0) | NA |
| Americas | |||||||
| Velasco et al. 2004 [35] | Brazil | 2000–2002 | Adults and children with ST or HM | 1036 | 328 (31.7) | 17 (1.6) | 18.7% |
| Islas-Munoz et al. 2018 [5] | Mexico | 2016–2017 | Adults with ST or HM | 496 | 135 (27.2) | 4 (0.8) | 8.0% |
| Europe | |||||||
| Anatoliotaki et al. 2004 [42] | Greece | 1995–2000 | Adults with ST | 157 | 54 (34.4) | 12 (7.6) | 85.7% |
| Schelenz et al. 2013 [48] | UK | 1997–2010 | Adults with ST or HM | 949 | 560 (59.0) | 26 (2.7) | 32.1% |
| Miedema et al. 2013 [34] |
Netherlands; Switzerland |
2004–2011 | Children with ST or HM and FN | 248 | 180 (72.6) | 0 (0.0) | NA |
| Horasan et al. 2011 [36] | Turkey | 2004–2009 | Adults with ST or HM and FN | 98 | 47 (48.0) | 3 (3.1) | NA |
| Kara et al. 2015 [46] | Turkey | 2005–2009 | Adults with HM and FN | 536 | 192 (35.8) | 7 (1.3) | 23.3% |
| Bodro et al. 2014 [47] | Spain | 2006–2011 | Adults with ST or HM | 1148 | NA | 13 (1.1) | 12.3% |
| Gedik et al. 2014 [40] | Turkey | 2010–2012 | Adults with HM and FN | 90 | 17 (18.9) | 4 (4.4) | NA |
| Western Pacific | |||||||
| Lai et al. 2003 [31] | Taiwan, China | 1999 | Children with ST or HM and FN | 46 | 11 (23.9) | 3 (6.5) | NA |
| Wang et al. 2005 [33] | Taiwan, China | 1999–2002 | Adults with HM | 418 | 87 (20.8) | 39 (9.3) | 73.6% |
| Huang et al. 2011 [29] | Taiwan, China | 2003–2005 | Adults with ST or HM | 588 | 153 (26.0) | 24 (4.1) | 55.8% |
| Baskaran et al. 2007 [32] | Malaysia | 2004–2005 | Adults with HM and FN | 73 | 29 (39.7) | 0 (0.0) | NA |
| Yamamoto et al. 2010 [39] | Japan | 2003–2007 | Adults with HM | 119 | 89 (74.8) | 14 (11.8) | 82.4% |
| Kang et al. 2012 [13] | South Korea |
2006–2007; 2008–2009 |
Adults with ST or HM | 1246 | 408 (32.7) | 59 (4.7) | 48.4% |
| Kwon et al. 2013 [45] | South Korea | 2009–2010 | Adults with HM | 243 | 122 (50.2) | 7 (2.9) | 63.6% |
| Chen et al. 2017 [44] | Taiwan, China | 2008–2013 | Adults with HM | 2090 | 841 (40.2) | 24 (1.1) | 42.1% |
| South-east Asia | |||||||
| Bhat et al. 2016 [37] | India | 2012–2014 | Adults with ST or HM and FN | 128 | 51 (39.8) | 10 (7.8) | 31.3% |
| Eastern Mediterranean | |||||||
| Greenberg et al. 2005 [50] | Israel | 1998–2002 | Children with ST or HM and FN | 132 | 39 (29.5) | 0 (0.0) | NA |
BSI bloodstream infection, GP Gram-positive, MRSA methicillin-resistant Staphylococcus aureus, ST solid tumors, HM hematological malignancy, FN febrile neutropenia, NA not applicable